Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

How do I diagnose and treat my patient’s amiodarone-induced thyrotoxicosis?

Nikita Jhawar, MD and Razvan Chirila, MD
Cleveland Clinic Journal of Medicine July 2023, 90 (7) 409-412; DOI: https://doi.org/10.3949/ccjm.90a.22084
Nikita Jhawar
Department of Internal Medicine, Mayo Clinic, Jacksonville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Razvan Chirila
Department of Internal Medicine, Mayo Clinic, Jacksonville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Early and late stages of amiodarone-induced thyrotoxicosis (AIT). (A) In early AIT, amiodarone blocks the conversion of thyroxine (T4) to triiodothyronine (T3), leading to increased levels of T4 and decreased levels of T3. Through feedback, the pituitary gland is stimulated to produce more thyroid-stimulating hormone (TSH), which promotes thyroid hormone production by the thyroid gland. (B) In late AIT, after the increased TSH production and stimulation of the thyroid gland, T3 and T4 levels both become elevated. Through negative feedback on the pituitary gland, less TSH is secreted.

Tables

  • Figures
    • View popup
    TABLE 1

    Features of type 1, type 2, and mixed amiodarone-induced thyrotoxicosis

    Type 1 AITType 2 AITMixed AIT
    Mechanism of diseaseExcess iodineDestructive inflammatory thyroiditisFeatures of both
    Underlying thyroid diseasePresentAbsentFeatures of both
    GoiterMultinodular or diffuse goiter normally presentInfrequent; may have small, diffuse, firm, or tender goiterFeatures of both
    TSH, early disease courseElevatedNormalVariable
    TSH, late disease courseElevatedNormalVariable
    Thyroid autoantibodiesPresentAbsentFeatures of both
    Radioactive iodine studiesNormal or increased uptakeLittle or no updateFeatures of both
    99mTc-MIBIIncreased uptakeDecreased uptakeFeatures of both
    Color-flow Doppler ultrasonographyHigh vascularityAbsent vascularityFeatures of both
    TreatmentThionamidesSteroidsCombination of both
    Spontaneous remissionNoPossibleFeatures of both
    Late hypothyroidismNoExtremely rareFeatures of both
    • 99mTc-MIBI = technetium Tc 99m methoxyisobutylisonitrile; TSH = thyroid-stimulating hormone

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 90 (7)
Cleveland Clinic Journal of Medicine
Vol. 90, Issue 7
1 Jul 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How do I diagnose and treat my patient’s amiodarone-induced thyrotoxicosis?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How do I diagnose and treat my patient’s amiodarone-induced thyrotoxicosis?
Nikita Jhawar, Razvan Chirila
Cleveland Clinic Journal of Medicine Jul 2023, 90 (7) 409-412; DOI: 10.3949/ccjm.90a.22084

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
How do I diagnose and treat my patient’s amiodarone-induced thyrotoxicosis?
Nikita Jhawar, Razvan Chirila
Cleveland Clinic Journal of Medicine Jul 2023, 90 (7) 409-412; DOI: 10.3949/ccjm.90a.22084
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • PHYSIOLOGY OF AMIODARONE-INDUCED THYROTOXICOSIS
    • TYPE 1 AMIODARONE-INDUCED THYROTOXICOSIS
    • TYPE 2 AMIODARONE-INDUCED THYROTOXICOSIS
    • MIXED AMIODARONE-INDUCED THYROTOXICOSIS
    • CONTINUATION OF AMIODARONE AFTER THYROTOXICOSIS
    • THE BOTTOM LINE
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Cardiology
  • Endocrinology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire